Five things for pharma marketers to know: Wednesday, July 18, 2018

Share this content:

Novartis has joined Pfizer in deciding not to increase drug prices for the rest of the year. The move came a week after Pfizer delayed price increases after being criticized by President Donald Trump. Novartis is already in the hot seat over its contract with former Trump lawyer Michael Cohen. (Bloomberg)


Martin Shkreli's former pharma company is losing money and looking at yet another name change. Vyera Pharmaceuticals, previously Turing Pharmaceuticals, lost more than $1 million in the first quarter after sales of Daraprim, whose price was hiked by more than 5,000% by Shkreli in 2015, continued to fall. Vyera, which changed its name last year, is considering another rebranding to Phoenixus. (STAT)


The FDA wants to modernize how electronic health data is used in clinical trials. The agency issued a draft guidance to help clinical investigators better integrate electronic and real-world data collected in routine care settings into clinical trials. (FDA)


Eli Lilly and Pfizer are celebrating positive results in their non-opioid painkiller's late-stage trial. The drug is being tested in patients suffering from osteoarthritis, but there are safety issues associated with its use. Despite that, Pfizer has signaled the drug is one of the leading late-stage drugs in its pipeline. (Endpoints News)


Bill Gates is promising $30 million to encourage companies to develop tests for early detection of Alzheimer's disease. Gates partnered with Leonard Lauder to launch the Diagnostics Accelerator program, which will award $30 million over three years to scientists and clinicians in academic settings, charities, and biotechnology companies developing early detection tests. (Reuters)

Share this content:
Scroll down to see the next article